Pharm
Fluconazole
search
Fluconazole
, Diflucan
See also
Antifungal Medication
Topical Antifungal
Isavuconazole
Itraconazole
Posaconazole
Voriconazole
Indications
Onychomycosis
Candida Infections
Yeast Vaginitis
Systemic
Candidiasis
Oropharyngeal
Candidiasis
(
Thrush
)
Candida
Esophagitis
Candida
Pyelonephritis
Systemic fungal infections (esp.
Immunocompromised
patients,
Neutropenia
,
HIV Infection
)
Coccidioidomycosis
Cryptococcosis
Other Fluconazole activity
Histoplasmosis
(variable activity)
Blastomycosis
Sporotrichosis
Contraindications
Voriconazole
coadministration
Resistant fungal strains
Candida krusei
Candida glabrata (some strains)
Aspergillosis
Fusarium
Mucorales or Zygomycetes (e.g. Mucor species, Rhizopus species)
Mechanism
Azole Antifungal
(triazole)
Inhibits fungal
CYP450
enzymes
Inhibits sterol demethylation
Blocks the synthesis of plasma membrane steroids (conversion from lanosterol to ergosterol)
Results in plasma membrane damage
Medications
Oral Tablets: 50, 100, 150, 200 mg
Suspension 10 mg/ml, 40 mg/ml
Dosing
Common Indications in Immunocompetent Patients
See below for
Thrush
dosing in infants
Tinea Versicolor
Adult: 400 mg orally for one dose (or 300 mg orally once weekly for 2 weeks)
Yeast Vaginitis
Adult: 150 mg orally for one dose
Recurrent in Adults
Start: 150 mg orally every third day for 3 doses
Next: 150 mg orally weekly for up to 6 months
Dosing
Indications in
Immunocompromised
Patients
See
Cryptococcal Meningitis
Oropharyngeal
Candidiasis
(
Thrush
)
Adult: 200 mg orally on Day 1, then 100 mg orally/IV daily for 14 days
Child: 6 mg/kg (up to 200 mg) orally/IV on Day 1, then 3 mg/kg (up to 100 mg) orally daily for 14 days
Esophageal Candidiasis
Start: 6 mg/kg (up to 200 mg) orally/IV on Day 1
Next: 3 mg/kg (up to 100 mg) orally/IV daily for 21 days (and at least 2 weeks after resolution)
May require increased dose up to 12 mg/kg (up to 200 to 400 mg) daily
Systemic
Candidiasis
Start: 12 mg/kg (up to 800 mg) orally/IV on day 1
Next: 6 to 12 mg/kg (up to 400 mg) orally/IV daily
Continue for 14 days after
Blood Culture
negative AND symptoms resolved
Candida
Pyelonephritis
Dose: 3 to 6 mg/kg (up to 200 to 400 mg) IV or orally daily for 14 days
Candida prophylaxis in severe
Neutropenia
Adult: 400 mg orally/IV daily until severe
Neutropenia
resolves
Coccidioidomycosis
Treatment and Prophylaxis in
HIV Infection
Adult: 400 mg orally/IV daily
Dosing
Renal
GFR <50 ml/min
Give initial loading dose (up to 400 mg)
Decrease maintenance dose to 50% of recommended dose
Hemodialysis
Give 100% of recommended dose after each
Hemodialysis
run
Give 50% of recommended dose on non-
Hemodialysis
days
Dosing
Other Historic Indications
Largely replaced by other systemic
Antifungal
s
Tinea Capitis
Daily: 6 mg/kg/day (up to 150 mg to 300 mg) daily for 3 to 6 weeks OR
Weekly: 6 mg/kg/day (up to 150 mg to 300 mg) weekly for 8 to 12 weeks
Onychomycosis
Adult: 150 to 300 mg (up to 450 mg) orally once per week
Child: 3 to 6 mg/kg once weekly
Course
Fingernail
: 3-6 months
Toenail
: 6-12 months
Adverse Effects
Common (5% of patients)
Nausea
Headache
Pruritus
Facial Edema
Serious (uncommon to rare)
Stevens Johnson Syndrome
Anaphylaxis
Leukopenia
Hypokalemia
QTc Prolongation
(
Torsades de Pointes
risk)
Hepatotoxicity
Liver Function Test
abnormalities
Safety
Considered safe in
Lactation
Pregnancy Category D
Pregnancy Category C only at low dose (150 mg once) for
Vaginal Candidiasis
As of 2016, evidence of
Miscarriage
risk, with even 1-2 doses
Previously thought safe in pregnancy if limited to occassional single dose
Mølgaard-Nielsen (2016) JAMA 315(1):58-67 +PMID:26746458 [PubMed]
Congenital abnormalities reported after higher dose first trimester exposure (400 to 800 mg/day)
Brachycephaly
Cleft Palate
Congenital Heart Disease
Pharmacokinetics
Excellent oral
Bioavailability
Not significantly affected by
Antacid
-induced higher gastric pH
Peak oral concentrations at 1-2 hours are similar to IV administration
Long
Elimination Half-Life
: 30 hours
Distribution
Penetrates cerebrospinal fluid (CSF) with concentrations reaching 50 to 90% of serum concentrations
Also penetrates eye and urine
Metabolism and excretion
Hepatic metabolism
Excreted unchanged in urine (80%)
Drug Interactions
Gene
ral
Absorption not affected by gastric pH
CYP2C9 Inhibitor
(strong)
CYP2C19 Inhibitor
(strong)
CYP3A4
Inhibitor (moderate)
Avoid with drugs that
Drugs That Prolong the QTc Interval
Erythromycin
Pimozide
Quinidine
INCREASES levels of other agents
Alfentanil
Benzodiazepine
s (significant sedation)
Calcium Channel Blocker
s
Celecoxib
Cyclosporine
Fentanyl
Florbiprofen
Fluvastatin
(limit to max of 20 mg/day)
Losartan
Lovastatin
Methadone
Phenytoin
Rifabutin
Simvastatin
Sirolimus
Sulfonylurea
s (e.g.
Glyburide
,
Glipizide
,
Hypoglycemia
risk)
Tacrolimus
Theophylline
Tofacitinib
(limit to max of 5 mg)
Tolbutamide
Warfarin
(bleeding risk)
Fluconazole levels DECREASED by other agents
Cimetidine
Rifampin
Fluconazole levels INCREASED by other agents
Hydrochlorothiazide
Monitoring
Onychomycosis
or
Yeast Vaginitis
No routine lab tests recommended
Some guidelines have recommended baseline labs
Complete Blood Count
(CBC)
Liver
transaminases (AST, ALT)
Serum Creatinine
Resources
Fluconazole Tablet or Suspension (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f694c617-3383-416c-91b6-b94fda371204
Fluconazole IV Solution (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd24a261-9c15-42b4-8040-89d2dbda174e
References
Hamilton (2020) Tarascon Pocket Pharmacopoeia
Olson (2020) Clinical
Pharmacology
, Medmaster, Miami, Fl, p. 120-1
(2012) Med Lett Drugs Ther 10(120): 61-8 [PubMed]
(1990) Med Lett Drugs Ther 32(818): 50 to 52 [PubMed]
Desai (1996) Am Fam Physician 54(4):1337-46 [PubMed]
Ely (2014) Am Fam Physician 90(10): 702-10 [PubMed]
Gupta (1999) J Am Acad Dermatol 41:237-49 [PubMed]
Friedlander (1999) Pediatr Infect Dis J 18(2):205-10 [PubMed]
Wildfeuer (1997) Mycoses 40:259-65 [PubMed]
Type your search phrase here